No significant increase in thrombotic risk following the widespread adoption of TPO-RAs in ITP: A comparative study
{{output}}
In patients with primary immune thrombocytopenia (ITP), the risk of thrombosis associated with thrombopoietin receptor agonists (TPO-RAs) remains debated. This study compared the thrombosis occurrence in ITP patients before and after the launch of TPO-RAs in C... ...
